Question
SARS, COVID – 19
Answer
SARS-CoV-2 is a novel coronavirus (family Coronaviridae, an enveloped, single-stranded, positive-sense RNA virus), the causative agent of COVID-19 (Coronavirus Disease 2019), which emerged in Wuhan, China, in late 2019 and rapidly spread to cause a global pandemic — its emergence and spread are considered together here as SARS-CoV-2/COVID-19, related to but genetically and clinically distinct from the earlier SARS-CoV (2002–03 SARS outbreak) and MERS-CoV.
Morphology: spherical, enveloped virion with characteristic club-shaped spike (S) glycoprotein projections giving the family its “crown” (corona) appearance on electron microscopy; the spike protein mediates attachment to the host ACE2 receptor and is the primary target of neutralizing antibody and vaccine design; other structural proteins include membrane (M), envelope (E), and nucleocapsid (N) proteins.
Transmission: primarily via respiratory droplets and aerosols, with additional risk from close contact and, to a lesser extent, contaminated surfaces (fomites).
Clinical features: ranges from asymptomatic/mild upper respiratory illness (fever, cough, sore throat, loss of smell/taste — anosmia/ageusia, a relatively distinctive early feature) to severe pneumonia, Acute Respiratory Distress Syndrome (ARDS), and multiorgan failure in severe cases, particularly in the elderly and those with comorbidities (diabetes, cardiovascular disease, obesity, immunosuppression).
Laboratory diagnosis:
- RT-PCR on nasopharyngeal/oropharyngeal swab — the gold-standard diagnostic test, detecting viral RNA.
- Rapid antigen detection tests — point-of-care, less sensitive but faster, useful for rapid triage/screening.
- Serology (IgM/IgG) — for retrospective/epidemiological assessment of past infection, not for acute diagnosis.
- CT chest — characteristic “ground-glass opacities” in moderate-severe pneumonia, used as an adjunct in some clinical settings.
Prevention: vaccination (multiple platforms developed at unprecedented speed — mRNA vaccines, viral vector vaccines, inactivated whole-virus vaccines, protein subunit vaccines); non-pharmaceutical measures (masking, physical distancing, hand hygiene, isolation of cases, quarantine of contacts) were central to outbreak control before widespread vaccination.
Treatment: largely supportive for mild disease; antivirals (e.g., remdesivir, nirmatrelvir-ritonavir) and immunomodulators (dexamethasone, tocilizumab) for moderate-severe disease, guided by disease severity and stage.
Public health significance: the pandemic prompted unprecedented global public health, vaccine-development, and international-cooperation responses, and remains a major reference point for pandemic preparedness planning against future emerging respiratory viral pathogens.